Ask Dr. Durie - Doctors' Edition: Proteasome Inhibitors in Multiple Myeloma

The following videos, presented by Medscape Oncology, are excerpts from virtual courses designed for certified medical education (CME) credits. Presented by IMF Chairman of the Board Brian G.M. Durie, M.D., these courses discuss the use of proteasome inhibitors in multiple myeloma.

To earn these CME credits,

1.  Register for free at Medscape.org.

2. Login to your Medscape account.

3. Enter this link into your browser: https://www.medscape.org/viewarticle/890372?src=acdmpart_imf_890372

4. View these virtual courses in their entirety.

5. Complete CME/ABIMMOC credit activities.



Section 1. What Are Proteasome Inhibitors and How Are They Used to Treat Multiple Myeloma?
Join Dr. Durie as he explains how proteasome inhibitors are used in multiple myeloma.
Brian G.M. Durie, MD

   


Section 2. How Are Proteasome Inhibitors Used in Frontline Therapy?
Learn how proteasome inhibitors are incorporated into treatment for patients with newly diagnosed multiple myeloma.
Brian G.M. Durie, MD; Shaji Kumar, MD

   


Section 3. Does High-Risk Disease Impact Proteasome Inhibitor-Based Therapy Selection?
Learn how proteasome inhibitors are used for patients with high-risk disease.
Brian G.M. Durie, MD; Saad Z. Usmani, MD

   


Section 4. How Are Proteasome Inhibitors Used in the Relapsed Setting?
Learn what to consider when selecting therapy for patients with relapsed multiple myeloma.
Brian G.M. Durie, MD; Thomas Martin, MD

   


Section 5. What Are the Adverse Events Associated With Proteasome Inhibitors And How Are They Managed?
Learn how to manage proteasome inhibitor-related adverse events.
Brian G.M. Durie, MD; Joseph Mikhael, MD

   


Section 6. Program Highlights
Dr. Durie summarizes key components for using proteasome inhibitors.
Brian G.M. Durie, MD